Advertisement
Advertisement
U.S. Markets open in 3 hrs 33 mins
Advertisement
Advertisement
Advertisement
Advertisement

Taysha Gene Therapies, Inc. (TSHA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.1300-0.0300 (-2.59%)
At close: 04:00PM EST
1.1400 +0.01 (+0.88%)
Pre-Market: 05:24AM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.1600
Open1.1500
Bid0.0000 x 1000
Ask0.0000 x 800
Day's Range1.1200 - 1.1900
52 Week Range1.0600 - 8.1400
Volume321,067
Avg. Volume729,053
Market Cap70.56M
Beta (5Y Monthly)1.40
PE Ratio (TTM)N/A
EPS (TTM)-3.8080
Earnings DateMar 29, 2023 - Apr 03, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est22.08
  • Simply Wall St.

    A Taysha Gene Therapies, Inc. (NASDAQ:TSHA) insider increased their holdings by 28% last year

    Viewing insider transactions for Taysha Gene Therapies, Inc.'s ( NASDAQ:TSHA ) over the last year, we see that insiders...

  • GlobeNewswire

    Taysha Gene Therapies Provides Update on TSHA-120 Program in Giant Axonal Neuropathy and a 2023 Corporate Outlook

    Type B end-of-Phase 2 meeting with U.S. Food and Drug Administration (FDA) provided additional clarity for TSHA-120 for the treatment of giant axonal neuropathy (GAN) ultra-rare disease program - FDA acknowledged MFM32 as an acceptable endpoint with a recommendation to dose additional patients in a double-blind, placebo-controlled design to support Biologics License Application (BLA) submission Organizational and business review by new management with operational, structural and personnel change

  • American City Business Journals

    Biotech signals potential pullback from 200-job Durham plant

    State officials have terminated an incentive agreement for a Texas-based biotech that had planned to invest $75 million in a manufacturing facility in Durham. The state's Economic Investment Committee, part of the North Carolina Department of Commerce, voted unanimously Tuesday to terminate a package awarded to Taysha Gene Therapies (Nasdaq: TSHA) in late 2020. The vote was in response to a letter the department received from the company requesting withdrawal from the state's Job Development Investment Grant program.

Advertisement
Advertisement